JPMorgan Chase & Co. Lowers Stock Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

JPMorgan Chase & Co. lowered its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 75.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 91,115 shares of the company's stock after selling 277,532 shares during the quarter. JPMorgan Chase & Co. owned about 0.18% of Tyra Biosciences worth $1,266,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. KLP Kapitalforvaltning AS purchased a new stake in shares of Tyra Biosciences during the 4th quarter worth approximately $31,000. US Bancorp DE acquired a new position in Tyra Biosciences in the fourth quarter valued at $50,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Tyra Biosciences during the fourth quarter worth about $149,000. EntryPoint Capital LLC acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth about $253,000. Finally, Franklin Resources Inc. purchased a new stake in shares of Tyra Biosciences in the 3rd quarter valued at about $278,000. Institutional investors and hedge funds own 84.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TYRA shares. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush reaffirmed an "outperform" rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, March 28th. Finally, UBS Group initiated coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $30.83.

Insider Activity

In related news, Director Nina S. Kjellson sold 5,401 shares of Tyra Biosciences stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total transaction of $74,317.76. Following the completion of the transaction, the director now directly owns 443,885 shares of the company's stock, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 15.40% of the company's stock.

Tyra Biosciences Trading Down 0.5 %

Shares of TYRA traded down $0.05 during mid-day trading on Thursday, hitting $10.25. The company's stock had a trading volume of 13,014 shares, compared to its average volume of 251,426. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60. The firm has a 50-day simple moving average of $9.87 and a 200 day simple moving average of $14.08. The firm has a market capitalization of $544.17 million, a P/E ratio of -6.37 and a beta of 1.19.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.05. As a group, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.